Results 141 to 150 of about 6,289,424 (361)

Regional Variability in Survival for Patients Diagnosed with Selected Central Nervous System Tumours in Canada

Current Oncology
Canada’s decentralized healthcare system may lead to regional disparities in survival among Canadians diagnosed with central nervous system (CNS) tumours.
Yifan Wu, Emily V. Walker, Yan Yuan
doaj   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Covariate balance-related propensity score weighting in estimating overall hazard ratio with distributed survival data. [PDF]

BMC Med Res Methodol, 2023
Huang C, Wei K, Wang C, Yu Y, Qin G.
europepmc   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

How to Clearly and Accurately Report Odds Ratio and Hazard Ratio in Diagnostic Research Studies? [PDF]

Korean J Radiol, 2022
Park SH, Han K.
europepmc   +1 more source

[O2‐01‐01]: Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard‐ratio analysis [PDF]

, 2005
Leon J. Thal, Ronald G. Thomas, Michael Grundman, David A. Bennett, Rachelle S. Doody, Steven H. Ferris, Douglas Galasko, Shelia Jin, Allan I. Levey, Ronald C. Petersen   +9 more
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?" [PDF]

, 2023
Violante Di Donato
  +6 more sources

Differential impact of SARS-CoV-2 infection during different outbreak periods on incident diabetes in Japan: a matched cohort study utilizing health insurance claims

Environmental Health and Preventive Medicine
Background: An increased risk of diabetes after COVID-19 exposure has been reported in Caucasians during the early phase of the pandemic, but the effects across viral variants and in non-Caucasians have not been evaluated.
Akiko Matsumoto, Sachiko Kodera, Tatsuya Matsuura, Yoko Takayama, Yuya Yamada, Akimasa Hirata   +5 more
doaj   +1 more source

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use. [PDF]

Trials, 2023
Prasad V, Kim MS, Haslam A.
europepmc   +1 more source